Literature DB >> 18504049

Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect.

Guy Haiman1, Hillel Pratt, Ariel Miller.   

Abstract

PURPOSE: To characterize the brain activity and associated cortical structures involved in pseudobulbar affect (PBA), a condition characterized by uncontrollable episodes of emotional lability in patients with multiple sclerosis (MS).
METHODS: Behavioral responses and event related potentials (ERP) in response to subjectively significant and neutral verbal stimuli were recorded from 33 subjects in 3 groups: 1) MS patients with PBA (MS+PBA); 2) MS patients without PBA (MS); 3) Healthy control subjects (HC). Statistical non-parametric mapping comparisons of ERP source current density distributions between groups were conducted separately for subjectively significant and for neutral stimuli.
RESULTS: Behavioral responses showed more impulsive performance in patients with PBA. As expected, almost all ERP waveform comparisons between the MS groups and controls were significant. Source analysis indicated significantly distinct activation in MS+PBA in the vicinity of the somatosensory and motor areas in response to neutral stimuli, and at pre-motor and supplementary motor areas in response to subjectively significant stimuli. Both subjectively significant and neutral stimuli evoked higher current density in MS+PBA compared to both other groups.
CONCLUSIONS: PBA of MS patients involves cortical structures related to sensory-motor and emotional processing, in addition to overactive involvement of motor cortical areas in response to neutral stimuli. SIGNIFICANCE: These results may suggest that a 'disinhibition' of a "gate control"-type mechanism for emotional expression may lead to the lower emotional expression threshold of pseudobulbar affect.

Entities:  

Mesh:

Year:  2008        PMID: 18504049     DOI: 10.1016/j.jns.2008.04.017

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

Review 1.  Current concepts in the pharmacotherapy of pseudobulbar affect.

Authors:  Erik P Pioro
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

Review 2.  Neurophysiological correlates of cognitive disturbances in multiple sclerosis.

Authors:  Letizia Leocani; Javier J Gonzalez-Rosa; Giancarlo Comi
Journal:  Neurol Sci       Date:  2010-11       Impact factor: 3.307

3.  Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis.

Authors:  Kathryn C Fitzgerald; Amber Salter; Tuula Tyry; Robert J Fox; Gary Cutter; Ruth Ann Marrie
Journal:  Neurol Clin Pract       Date:  2018-12

4.  Fractional Diffusion Based Modelling and Prediction of Human Brain Response to External Stimuli.

Authors:  Hamidreza Namazi; Vladimir V Kulish
Journal:  Comput Math Methods Med       Date:  2015-05-18       Impact factor: 2.238

5.  Effective use of sertraline for pathological laughing after severe vasospasm due to aneurysmal subarachnoid hemorrhage: case report.

Authors:  Hayato Takeuchi; Kazuhide Iwamoto; Mao Mukai; Tomoaki Fujita; Hitoshi Tsujino; Yoshihiro Iwamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-08       Impact factor: 1.742

Review 6.  Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.

Authors:  Erik P Pioro
Journal:  Neurol Ther       Date:  2014-06-17

7.  Altered resting-state functional activity in isolated pontine infarction patients with pathological laughing and crying.

Authors:  Tao Liu; Jianjun Li; Shixiong Huang; Changqinq Li; Zhongyan Zhao; Guoqiang Wen; Feng Chen
Journal:  Oncotarget       Date:  2017-07-17

8.  Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report.

Authors:  Fletcher Graham Young; Diep Nguyen
Journal:  J Med Case Rep       Date:  2020-12-04

Review 9.  Pseudobulbar affect: prevalence and management.

Authors:  Aiesha Ahmed; Zachary Simmons
Journal:  Ther Clin Risk Manag       Date:  2013-11-29       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.